The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression

Shock

Volumn 26, Issue 6, 2006, Pages 544-550

  O'Dwyer, Michael J ^a,b   Mankan, Arun K ^b   Stordeur, Patrick ^c   O'Connell, Brian ^a   Duggan, Edel ^b   White, Mary ^a   Kelleher, Dermot P ^b   McManus, Ross ^b   Ryan, Thomas ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ERASME HOSPITAL   (Belgium)

Author keywords

Cytokines; Interferon type II; RT PCR; Sepsis syndrome; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INOTROPIC AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 4; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTEREMIA; CLUSTER ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; SEPTIC SHOCK;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEPSIS; SHOCK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751250175     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000235091.38174.8d     Document Type: Article

References (35)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
3. Cohen J: The immunopathogenesis of sepsis. Nature 420:885-891, 2002.
4. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP: Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170-173, 1997.
5. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M: Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351:950-953, 1998.
6. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681, 1997.
7. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, Mougin B, Lepape A: Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 33:31-38, 2005.
8. Stordeur P, Poulin LF, Craciun L, Zhou L, Schandene L, de Lavareille A, Goriely S, Goldman M: Cytokine mRNA quantification by real-time PCR. J Immunol Methods 259:55-64, 2002.
9. Pachot A, Monneret G, Voirin N, Leissner P, Venet F, Bohe J, Payen D, Bienvenu J, Mougin B, Lepape A: Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin Immunol 114:61-69, 2005.
10. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963, 1993.
11. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca S, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710, 1996.
12. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001.
13. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451, 1991.
14. Bjerre A, Brusletto B, Hoiby EA, Kierulf P, Brandtzaeg P: Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med 32:433-438, 2004.
15. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697-1702, 1996.
16. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M: CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 23:1461-1469, 1995.
17. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-742, 1996.
18. Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol 15:749-795, 1997.
19. Deng JC, Zeng X, Newstead M, Moore TA, Tsai WC, Thannickal VJ, Standiford TJ: STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection. J Immunol 173:4075-4083, 2004.
20. Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S, Mochizuki H: Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg 182:491-497, 2001.
21. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP: Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother 48:4513-4519, 2004.
22. Haas N, Hauptmann S, Paralikoudi D, Muche M, Kolde G: Interferon-gamma treatment induces granulomatous tissue reaction in a case of localized cutaneous leishmaniasis. Am J Dermatopathol 24:319-323, 2002.
23. Barral-Netto M, Santos S, Santos I, von Sohsten R, Bittencourt AL, Carvalho EM, Barral A, Waters M: Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy. Acta Trop 72:185-201, 1999.
24. Condos R, Rom WN, Schluger NW: Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513-1515, 1997.
25. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, Steinmann GG: Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 26:434-439, 1998.
26. Polk HC Jr, Cheadle WG, Livingston DH, Rodriguez JL, Starko KM, Izu AE, Jaffe HS, Sonnenfeld G: A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 163:191-196, 1992.
27. Nakos G, Malamou-Mitsi VD, Lachana A, Karassavoglou A, Kitsiouli E, Agnandi N, Lekka ME: Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med 30:1488-1494, 2002.
28. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH: The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16:495-521, 1998.
29. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 176:1387-1398, 1992.
30. Heinzel FP, Hujer AM, Ahmed FN, Rerko RM: In vivo production and function of IL-12 p40 homodimers. J Immunol 158:4381-4388, 1997.
31. Vanden Eijnden S, Goriely S, De Wit D, Willems F, Goldman M: IL-23 upregulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 35:469-475, 2005.
32. Wu CY, Demeure C, Kiniwa M, Gately M, Delespesse G: IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J Immunol 151:1938-1949, 1993.
33. Swain SL, Weinberg AD, English M, Huston G: IL-4 directs the development of Th2-like helper effectors. J Immunol 145:3796-3806, 1990.
34. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 274:172-177, 1995.
35. Damas P, Canivet JL, de Groote D, Vrindts Y, Albert A, Franchimont P, Lamy M: Sepsis and serum cytokine concentrations. Crit Care Med 25:405-412, 1997.